MCID: DNG002
MIFTS: 66

Dengue Hemorrhagic Fever

Categories: Blood diseases, Infectious diseases

Aliases & Classifications for Dengue Hemorrhagic Fever

MalaCards integrated aliases for Dengue Hemorrhagic Fever:

Name: Dengue Hemorrhagic Fever 39 12 56 3 15 17
Severe Dengue 45 74
Dhf 12 3
Dengue Haemorrhagic Fever 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12206
MeSH 45 D019595
NCIt 51 C34683
SNOMED-CT 69 20927009
ICD10 34 A91
UMLS 74 C0019100

Summaries for Dengue Hemorrhagic Fever

Disease Ontology : 12 A dengue disease that occurs when a person experiences a second infection with a heterologous Dengue virus serotype, which is transmitted by Aedes mosquito bite. The infection has symptom hemorrhagic lesions of the skin, has symptom thrombocytopenia, has symptom reduction in the fluid part of the blood, and has symptom high fever.

MalaCards based summary : Dengue Hemorrhagic Fever, also known as severe dengue, is related to acute liver failure and japanese encephalitis, and has symptoms including thrombocytopenia, high fever and hemorrhagic lesions of the skin. An important gene associated with Dengue Hemorrhagic Fever is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Ketotifen and Histamine have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and endothelial, and related phenotypes are hematopoietic system and immune system

CDC : 3 Dengue

Related Diseases for Dengue Hemorrhagic Fever

Diseases related to Dengue Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 395)
# Related Disease Score Top Affiliating Genes
1 acute liver failure 31.0 ALB F2 GPT
2 japanese encephalitis 30.6 CD209 STAT1 TNF
3 compartment syndrome 30.6 ALB F2 TNF
4 cholecystitis 30.6 ALB F2 GPT
5 infantile liver failure syndrome 1 30.6 ALB F2 GPT
6 acute pancreatitis 30.5 CXCL8 IL10 IL6
7 hemophagocytic lymphohistiocytosis 30.4 CXCL8 IFNG IL10 TNF
8 eclampsia 30.4 ALB F2 TNF
9 dengue shock syndrome 30.3 CMA1 HLA-A HLA-DRB1 IL6 TNF
10 myocarditis 30.3 HLA-B IL6 TNF
11 acute disseminated encephalomyelitis 30.2 HLA-B HLA-DRB1 IL10
12 acute respiratory distress syndrome 30.1 CXCL8 IL6 TNF
13 aspergillosis 30.0 CD209 IFNG IL10 TNF
14 purpura 29.9 F2 F3 IL6 TNF
15 crohn's colitis 29.9 CXCL8 IFNG TNF
16 pneumonia 29.8 CXCL8 IL10 IL6 TNF
17 fasciitis 29.7 CXCL8 IL6 TNF
18 kawasaki disease 29.7 ALB FCGR2A IL10 IL6 TNF
19 filariasis 29.7 ALB IFNG IL10 IL6 TNF
20 typhoid fever 29.6 ALB F2 IFNG IL6 TNF
21 hepatitis a 29.6 ALB F2 GPT IFNG IL10 TNF
22 peritonitis 29.3 ALB CXCL8 F2 IL10 IL6 TNF
23 respiratory failure 29.2 ALB CXCL8 F3 TNF
24 acquired immunodeficiency syndrome 29.2 ALB HLA-B IFNG IL10 IL6 TNF
25 diabetes mellitus 28.5 ALB HLA-A HLA-B HLA-DRB1 IFNG IL6
26 malaria 28.0 ALB CXCL8 F3 FCGR2A HLA-A HLA-B
27 dengue disease 12.3
28 dengue virus 11.7
29 endomyocardial fibrosis 10.5 IL10 TNF
30 punctate inner choroidopathy 10.5 IL10 TNF
31 multifocal choroiditis 10.5 IL10 TNF
32 tropical endomyocardial fibrosis 10.5 IL10 TNF
33 microscopic polyangiitis 10.5 HLA-DRB1 TNF
34 hepatoportal sclerosis 10.5 F2 GPT
35 thrombocytopenia 10.5
36 juvenile myasthenia gravis 10.5 HLA-DRB1 IL10
37 leech infestation 10.5 F2 F3
38 prothrombin deficiency 10.5 F2 F3
39 cephalosporin allergy 10.5 IFNG IL10
40 hyperlucent lung 10.5 IFNG IL10
41 cerebral falx meningioma 10.5 F2 F3
42 intestinal impaction 10.5 F2 F3
43 sporotrichosis 10.5 IFNG IL10
44 rere-related disorders 10.5
45 cerebral sinovenous thrombosis 10.5 F2 F3
46 staphylococcal toxic shock syndrome 10.5 IFNG TNF
47 heparin-induced thrombocytopenia 10.5 F3 FCGR2A
48 antipyrine metabolism 10.5 ALB F2
49 epstein-barr virus hepatitis 10.4 ALB F2
50 abdominal tuberculosis 10.4 ALB F2

Graphical network of the top 20 diseases related to Dengue Hemorrhagic Fever:



Diseases related to Dengue Hemorrhagic Fever

Symptoms & Phenotypes for Dengue Hemorrhagic Fever

Symptoms:

12
  • thrombocytopenia
  • high fever
  • hemorrhagic lesions of the skin
  • reduction in the fluid part of the blood

MGI Mouse Phenotypes related to Dengue Hemorrhagic Fever:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 CMA1 F2 F3 FCGR2A IFNG IL10
2 immune system MP:0005387 9.96 CMA1 F2 F3 FCGR2A IFNG IL10
3 digestive/alimentary MP:0005381 9.91 ALB F2 IFNG IL10 IL6 STAT1
4 muscle MP:0005369 9.7 ALB F3 IFNG IL10 IL6 STAT1
5 neoplasm MP:0002006 9.5 ALB F3 IFNG IL10 IL6 STAT1
6 skeleton MP:0005390 9.23 F2 FCGR2A GPT IFNG IL10 IL6

Drugs & Therapeutics for Dengue Hemorrhagic Fever

Drugs for Dengue Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
2
Histamine Approved, Investigational Phase 4 51-45-6 774
3
Histamine Phosphate Phase 4 51-74-1 65513
4 Anti-Allergic Agents Phase 4
5 Neurotransmitter Agents Phase 4
6 Histamine H1 Antagonists Phase 4
7 Antipruritics Phase 4
8 Dermatologic Agents Phase 4
9 Histamine Antagonists Phase 4
10
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 6474909
11 Pharmaceutical Solutions Phase 3,Phase 2
12 Antiparasitic Agents Phase 2, Phase 3
13 Anti-Infective Agents Phase 2, Phase 3
14 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
15 Immunologic Factors Phase 3,Phase 2,Phase 1
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
17
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
18
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
19
Ribavirin Approved Phase 2 36791-04-5 37542
20
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
21 Antimetabolites Phase 2
22 Antiviral Agents Phase 2
23 Hydrocortisone 17-butyrate 21-propionate Phase 2
24 Hydrocortisone hemisuccinate Phase 2
25 Hemostatics Phase 2
26 Coagulants Phase 2
27 Antibodies Phase 1, Phase 2,Phase 2,Not Applicable
28 Immunoglobulins Phase 1, Phase 2,Phase 2,Not Applicable
29
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
30
Aluminum sulfate Approved Phase 1 10043-01-3
31
Varespladib methyl Investigational Phase 1 172733-08-3
32 Gastrointestinal Agents Phase 1
33 Antacids Phase 1
34 Anti-Ulcer Agents Phase 1
35 Adjuvants, Immunologic Phase 1
36
Permethrin Approved, Investigational Not Applicable 52645-53-1 40326
37 Rho(D) Immune Globulin Not Applicable
38 gamma-Globulins Not Applicable
39 Immunoglobulins, Intravenous Not Applicable
40 Endothelial Growth Factors
41 Mitogens

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
4 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
5 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
6 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
7 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
8 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
9 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Completed NCT02979535 Phase 3
10 Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue Completed NCT03423173 Phase 3
11 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
12 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
13 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
14 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3 TDV Placebo
15 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults Not yet recruiting NCT03771963 Phase 3
16 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
17 Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
18 Celgosivir as a Treatment Against Dengue Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
19 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
20 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
21 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
22 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
23 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
24 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
25 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
26 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
27 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
28 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
29 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
30 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
31 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
32 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Completed NCT00468858 Phase 2
33 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore Completed NCT02425098 Phase 2
34 Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants Completed NCT02302066 Phase 2 TDV Placebo
35 Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
36 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
37 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
38 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
39 Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Recruiting NCT03432442 Phase 2 Ivermectin
40 Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults Recruiting NCT03746015 Phase 2
41 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Active, not recruiting NCT02824198 Phase 2
42 Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age Active, not recruiting NCT02628444 Phase 2
43 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule Active, not recruiting NCT02623725 Phase 2
44 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Active, not recruiting NCT03110770 Phase 2
45 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
46 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Not yet recruiting NCT02741128 Phase 2
47 IC14 in Adult Patients With Dengue Fever Withdrawn NCT03875560 Phase 2 Placebo
48 Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus Completed NCT00458120 Phase 1
49 A Study of Balapiravir in Patients With Dengue Virus Infection Completed NCT01096576 Phase 1 balapiravir [RO4588161];placebo
50 Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever Completed NCT01224639 Phase 1

Search NIH Clinical Center for Dengue Hemorrhagic Fever

Cochrane evidence based reviews: severe dengue

Genetic Tests for Dengue Hemorrhagic Fever

Anatomical Context for Dengue Hemorrhagic Fever

MalaCards organs/tissues related to Dengue Hemorrhagic Fever:

42
Liver, Skin, Endothelial, Lung, Monocytes, Heart, Testes

Publications for Dengue Hemorrhagic Fever

Articles related to Dengue Hemorrhagic Fever:

(show top 50) (show all 726)
# Title Authors Year
1
Increased Carotid Intima-Media Thickness in Children with a History of Dengue Hemorrhagic Fever. ( 30675845 )
2019
2
The effectiveness of health education using audiovisual media on increasing family behavior in preventing dengue hemorrhagic fever (DHF). ( 30745163 )
2019
3
Genome-wide profiling of mRNA and lncRNA expression in dengue fever and dengue hemorrhagic fever. ( 30868055 )
2019
4
Evaluation of biochemical and haematological changes in dengue fever and dengue hemorrhagic fever in Sri Lankan children: a prospective follow up study. ( 30935373 )
2019
5
Ultrastructural Features of Human Liver Specimens from Patients Who Died of Dengue Hemorrhagic Fever. ( 31013708 )
2019
6
Seroepidemiology of dengue virus infection among adults during the ending phase of a severe dengue epidemic in southern Taiwan, 2015. ( 31014263 )
2019
7
Risk of severe dengue is higher in patients with sickle cell disease: a scoping review. ( 30476342 )
2019
8
"Honeycomb" pattern of gallbladder wall thickening - A forward step in early diagnosis of "Severe Dengue Fever". ( 31000936 )
2019
9
Spatiotemporal patterns and climatic drivers of severe dengue in Thailand. ( 30625675 )
2019
10
Comprehensive treatment in severe dengue during preterm and term labor: could tocolysis be useful? ( 30626246 )
2019
11
A 20-Gene Set Predictive of Progression to Severe Dengue. ( 30699342 )
2019
12
Severe Dengue Prognosis Using Human Genome Data and Machine Learning. ( 30716030 )
2019
13
Plasma cell-free DNA: a potential biomarker for early prediction of severe dengue. ( 30871553 )
2019
14
Comments on the Study "The Sensitivity, Specificity and Accuracy of Warning Signs in Predicting Severe Dengue, the Severe Dengue Prevalence and Its Associated Factors". ( 30875811 )
2019
15
Reply to Comments on the Study "The Sensitivity, Specificity and Accuracy of Warning Signs in Predicting Severe Dengue, the Severe Dengue Prevalence and its Associated Factors". ( 30999608 )
2019
16
Different Associations between DC-SIGN Promoter-336G/A (rs4804803) Polymorphism with Severe Dengue in Asians and South-Central Americans: a Meta-Analysis. ( 31027310 )
2019
17
Lessons learnt from managing a case of dengue hemorrhagic fever complicated with acute liver failure and acute kidney injury: a case report. ( 30089506 )
2018
18
Clinical profile and predictors of Severe Dengue disease: A study from South India. ( 30510647 )
2018
19
Association of Single-Nucleotide Polymorphisms in Immune-Related Genes with Development of Dengue Hemorrhagic Fever in a Mexican Population. ( 29130827 )
2018
20
Dengue Hemorrhagic Fever Virus in Saudi Arabia: A Review. ( 29319426 )
2018
21
Prospective forecasts of annual dengue hemorrhagic fever incidence in Thailand, 2010-2014. ( 29463757 )
2018
22
Concurrent methicillin-resistant Staphylococcus aureus septicemia and pyomyositis in a patient with dengue hemorrhagic fever: a case report. ( 29486726 )
2018
23
Climate variability and dengue hemorrhagic fever in Southeast Sulawesi Province, Indonesia. ( 29549613 )
2018
24
Platelet Count, D-Dimer, Component Therapy and Dengue Hemorrhagic Fever. ( 29622891 )
2018
25
The Autoimmune Mechanism in Dengue Hemorrhagic Fever. ( 29686179 )
2018
26
Culture-positive unilateral panophthalmitis in a serology-positive case of dengue hemorrhagic fever. ( 29941760 )
2018
27
Climate Variability and Dengue Hemorrhagic Fever in Hanoi, Viet Nam, During 2008 to 2015. ( 30045631 )
2018
28
Platelet Transfusion Related Panophthalmitis and Endophthalmitis in Patients with Dengue Hemorrhagic Fever. ( 30062992 )
2018
29
Is Total Serum Nitrite and Nitrate (NOx) Level in Dengue Patients a Potential Prognostic Marker of Dengue Hemorrhagic Fever? ( 30069272 )
2018
30
Early Detection of Plasma Leakage in Dengue Hemorrhagic Fever. ( 30333266 )
2018
31
Comment on: Culture-positive unilateral panophthalmitis in a serology-2 positive case of dengue hemorrhagic fever. ( 30355903 )
2018
32
Response to comment on: Culture-positive unilateral panophthalmitis in a serology-2 positive case of dengue hemorrhagic fever. ( 30355904 )
2018
33
Management of Diabetic Ketoacidosis with Dengue Hemorrhagic Fever. ( 30473969 )
2018
34
Diabetic patients suffering dengue are at risk for development of dengue shock syndrome/severe dengue: Emphasizing the impacts of co-existing comorbidity(ies) and glycemic control on dengue severity. ( 30146413 )
2018
35
Two fatal cases of Aeromonas dhakensis bacteremia and necrotizing fasciitis in severe dengue patients. ( 29859782 )
2018
36
Elimination of Falciparum Malaria and Emergence of Severe Dengue: An Independent or Interdependent Phenomenon? ( 29899735 )
2018
37
Validation of Serum Aminotransferases Levels to Define Severe Dengue Fever in Children. ( 30345242 )
2018
38
Fatal Intracranial Hemorrhage in a Patient with Severe Dengue Fever. ( 29492121 )
2018
39
Analyses of clinical and laboratory characteristics of dengue adults at their hospital presentations based on the World Health Organization clinical-phase framework: Emphasizing risk of severe dengue in the elderly. ( 28734676 )
2018
40
Clinical and Laboratory Factors Associated with Severe Dengue: A Case-Control Study of Hospitalized Children. ( 29059411 )
2018
41
A novel predictor of severe dengue: The aspartate aminotransferase/platelet count ratio index (APRI). ( 29315684 )
2018
42
Development of a Prognostic Prediction Model to Determine Severe Dengue in Children. ( 29344875 )
2018
43
Serum metabolome changes in adult patients with severe dengue in the critical and recovery phases of dengue infection. ( 29364889 )
2018
44
Spontaneous calf haematoma in severe dengue. ( 29374645 )
2018
45
Metformin Use and Severe Dengue in Diabetic Adults. ( 29463812 )
2018
46
Severe Dengue: Developing a Universally Applicable Simple Prediction Model. ( 29637462 )
2018
47
Targeted Interventions in Critically Ill Children with Severe Dengue. ( 29657372 )
2018
48
Definitions for warning signs and signs of severe dengue according to the WHO 2009 classification: Systematic review of literature. ( 29691914 )
2018
49
Genome-Wide Analysis to Identify HLA Factors Potentially Associated With Severe Dengue. ( 29692780 )
2018
50
Prediction of mortality in severe dengue cases. ( 29783955 )
2018

Variations for Dengue Hemorrhagic Fever

Expression for Dengue Hemorrhagic Fever

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Hemorrhagic Fever patients vs. healthy controls: 35 (show top 50) (show all 120)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CD38 CD38 molecule Blood + 4.80 0.000
2 IFI27 interferon, alpha-inducible protein 27 Blood + 4.71 0.000
3 RRM2 ribonucleotide reductase M2 Blood + 4.63 0.000
4 IGHM immunoglobulin heavy constant mu Blood + 4.61 0.000
5 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.47 0.000
6 CAV1 caveolin 1, caveolae protein, 22kDa Blood + 4.41 0.000
7 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 Blood + 4.31 0.000
8 XIST X inactive specific transcript (non-protein coding) Blood - 4.31 0.023
9 CEP55 centrosomal protein 55kDa Blood + 4.28 0.000
10 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.21 0.000
11 SHCBP1 SHC SH2-domain binding protein 1 Blood + 4.13 0.000
12 PBK PDZ binding kinase Blood + 4.13 0.000
13 IGKV3-20 immunoglobulin kappa variable 3-20 Blood + 4.13 0.000
14 TYMS thymidylate synthetase Blood + 4.07 0.000
15 CDCA2 cell division cycle associated 2 Blood + 4.06 0.000
16 MKI67 marker of proliferation Ki-67 Blood + 4.00 0.000
17 CYAT1 immunoglobulin lambda light chain-like Blood + 3.98 0.000
18 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.98 0.000
19 NOV nephroblastoma overexpressed Blood - 3.97 0.000
20 ZWINT ZW10 interacting kinetochore protein Blood + 3.96 0.000
21 CDK1 cyclin-dependent kinase 1 Blood + 3.92 0.000
22 HMMR hyaluronan-mediated motility receptor (RHAMM) Blood + 3.90 0.000
23 SDC1 syndecan 1 Blood + 3.89 0.000
24 SPC25 SPC25, NDC80 kinetochore complex component Blood + 3.84 0.000
25 NCAPG non-SMC condensin I complex, subunit G Blood + 3.84 0.000
26 TK1 thymidine kinase 1, soluble Blood + 3.82 0.000
27 CDC20 cell division cycle 20 Blood + 3.80 0.000
28 TNFRSF17 tumor necrosis factor receptor superfamily, member 17 Blood + 3.80 0.000
29 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) Blood + 3.80 0.000
30 TOP2A topoisomerase (DNA) II alpha Blood + 3.80 0.000
31 PI3 peptidase inhibitor 3, skin-derived Blood - 3.76 0.000
32 GLDC glycine dehydrogenase (decarboxylating) Blood + 3.75 0.000
33 IGLJ3 immunoglobulin lambda joining 3 Blood + 3.75 0.000
34 SESN3 sestrin 3 Blood - 3.75 0.000
35 KIF2C kinesin family member 2C Blood + 3.74 0.000
36 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.72 0.000
37 CDKN3 cyclin-dependent kinase inhibitor 3 Blood + 3.71 0.000
38 KIAA0101 KIAA0101 Blood + 3.71 0.000
39 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood + 3.71 0.034
40 CNTNAP3 contactin associated protein-like 3 Blood - 3.70 0.000
41 CENPA centromere protein A Blood + 3.69 0.000
42 TTK TTK protein kinase Blood + 3.67 0.000
43 ASPM abnormal spindle microtubule assembly Blood + 3.66 0.000
44 KIF11 kinesin family member 11 Blood + 3.64 0.000
45 IGL immunoglobulin lambda locus Blood + 3.64 0.000
46 CCNB2 cyclin B2 Blood + 3.61 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.60 0.000
48 CDC6 cell division cycle 6 Blood + 3.60 0.000
49 SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 Blood + 3.60 0.000
50 DUSP5 dual specificity phosphatase 5 Blood + 3.60 0.000
Search GEO for disease gene expression data for Dengue Hemorrhagic Fever.

Pathways for Dengue Hemorrhagic Fever

Pathways related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 CD209 CXCL8 FCGR2A HLA-A HLA-B HLA-DRB1
2
Show member pathways
13.57 CXCL8 F2 IFNG IL10 IL6 STAT1
3
Show member pathways
13.3 CXCL8 HLA-A HLA-B HLA-DRB1 IFNG IL10
4
Show member pathways
13.14 CXCL8 IFNG IL10 IL6 STAT1 STAT2
5
Show member pathways
13.02 HLA-A HLA-B IL6 STAT1 STAT2 TNF
6
Show member pathways
13.01 CXCL8 HLA-A HLA-B IL6 STAT1 STAT2
7 12.86 CXCL8 IFNG IL6 STAT1 STAT2
8
Show member pathways
12.65 HLA-DRB1 IFNG IL10 IL6 STAT1 TNF
9
Show member pathways
12.65 CXCL8 HLA-A HLA-B HLA-DRB1 IFNG IL10
10
Show member pathways
12.64 F2 IFNG IL10 IL6 STAT1 TNF
11 12.61 IFNG IL10 STAT1 STAT2 TNF
12
Show member pathways
12.59 HLA-A HLA-B HLA-DRB1 IFNG STAT1 STAT2
13
Show member pathways
12.58 IFNG IL10 IL6 TNF
14
Show member pathways
12.52 HLA-A HLA-B IFNG TNF
15
Show member pathways
12.45 IFNG IL10 IL6 STAT1 STAT2
16 12.42 HLA-A HLA-B HLA-DRB1 IL6 TNF
17
Show member pathways
12.4 ALB F2 IFNG IL6 TNF
18
Show member pathways
12.38 CXCL8 IFNG IL6 STAT1 TNF
19
Show member pathways
12.37 CXCL8 IFNG IL6 TNF
20
Show member pathways
12.34 IFNG IL6 STAT1 STAT2
21
Show member pathways
12.29 CXCL8 F3 IL6 STAT1 TNF
22
Show member pathways
12.26 FCGR2A HLA-DRB1 IFNG IL10 STAT1 TNF
23
Show member pathways
12.25 IFNG STAT1 STAT2 TNF
24
Show member pathways
12.25 CXCL8 IFNG IL6 STAT1 TNF
25 12.23 IFNG IL6 STAT1 TNF
26 12.22 CXCL8 IL10 IL6 TNF
27 12.21 CXCL8 HLA-A HLA-B IL6
28 12.2 CD209 FCGR2A HLA-A HLA-B HLA-DRB1
29
Show member pathways
12.17 CD209 IL10 IL6 STAT1 STAT2 TNF
30
Show member pathways
12.14 CXCL8 IFNG IL10 IL6 STAT1 STAT2
31 12.12 IL6 STAT1 STAT2 TNF
32 12.11 FCGR2A IFNG STAT1 STAT2 TNF
33
Show member pathways
12.1 F2 FCGR2A IFNG IL6 TNF
34 12.06 CXCL8 FCGR2A IFNG IL6 TNF
35
Show member pathways
12.04 HLA-A HLA-DRB1 IFNG STAT1
36 12.03 CXCL8 IL10 IL6 STAT1 TNF
37
Show member pathways
12 IFNG IL10 IL6 STAT1 STAT2 TNF
38 11.95 CXCL8 IFNG IL6
39 11.95 CXCL8 F3 IL6 STAT1 TNF
40 11.93 IFNG IL10 IL6 STAT1 STAT2
41 11.92 CXCL8 IFNG IL10 IL6 TNF
42 11.91 HLA-DRB1 IL6 TNF
43 11.88 CXCL8 IFNG IL6 STAT1
44 11.88 CXCL8 HLA-DRB1 IFNG IL6 TNF
45 11.86 CD209 FCGR2A IFNG IL10 IL6 TNF
46 11.85 CXCL8 IFNG IL6
47 11.84 CXCL8 IL10 IL6 TNF
48 11.82 IFNG IL10 TNF
49
Show member pathways
11.82 CXCL8 HLA-A HLA-B IFNG IL10 IL6
50
Show member pathways
11.79 CXCL8 IFNG TNF

GO Terms for Dengue Hemorrhagic Fever

Cellular components related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.73 CD209 F3 HLA-A HLA-B HLA-DRB1 TNF
2 extracellular region GO:0005576 9.65 ALB CD209 CMA1 CXCL8 F2 F3
3 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-A HLA-B HLA-DRB1
4 MHC class I protein complex GO:0042612 9.37 HLA-A HLA-B
5 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-A HLA-B HLA-DRB1
6 extracellular space GO:0005615 9.32 ALB CMA1 CXCL8 F2 F3 GPT

Biological processes related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.97 CD209 HLA-B HLA-DRB1 STAT1 STAT2
2 regulation of signaling receptor activity GO:0010469 9.85 CXCL8 F2 IFNG IL10 IL6 TNF
3 defense response to virus GO:0051607 9.81 IFNG IL6 STAT1 STAT2
4 cellular response to lipopolysaccharide GO:0071222 9.78 CXCL8 IL10 IL6 TNF
5 response to glucocorticoid GO:0051384 9.76 IL10 IL6 TNF
6 humoral immune response GO:0006959 9.73 IFNG IL6 TNF
7 positive regulation of smooth muscle cell proliferation GO:0048661 9.72 IL6 STAT1 TNF
8 interleukin-6-mediated signaling pathway GO:0070102 9.63 IL6 STAT1
9 negative regulation of growth of symbiont in host GO:0044130 9.63 IL10 TNF
10 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.62 IL10 TNF
11 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.62 IFNG STAT1
12 type I interferon signaling pathway GO:0060337 9.62 HLA-A HLA-B STAT1 STAT2
13 response to molecule of bacterial origin GO:0002237 9.61 CXCL8 IL10
14 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.61 HLA-A HLA-B
15 negative regulation of lipid storage GO:0010888 9.6 IL6 TNF
16 endothelial cell apoptotic process GO:0072577 9.59 IL10 TNF
17 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.58 HLA-A HLA-B
18 antigen processing and presentation GO:0019882 9.56 CD209 HLA-A HLA-B HLA-DRB1
19 immune response GO:0006955 9.56 CXCL8 HLA-A HLA-B HLA-DRB1 IFNG IL10
20 interferon-gamma-mediated signaling pathway GO:0060333 9.55 HLA-A HLA-B HLA-DRB1 IFNG STAT1
21 negative regulation of cytokine secretion involved in immune response GO:0002740 9.54 IL10 TNF
22 positive regulation of neuroinflammatory response GO:0150078 9.52 IL6 TNF
23 protection from natural killer cell mediated cytotoxicity GO:0042270 9.49 HLA-A HLA-B
24 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 IFNG TNF
25 receptor biosynthetic process GO:0032800 9.43 IL10 TNF
26 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 IFNG TNF
27 cytokine-mediated signaling pathway GO:0019221 9.17 CXCL8 F3 IL10 IL6 STAT1 STAT2

Molecular functions related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.35 CXCL8 IFNG IL10 IL6 TNF
2 peptide antigen binding GO:0042605 8.92 CD209 HLA-A HLA-B HLA-DRB1

Sources for Dengue Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....